A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.

Published in: Pharmacoepidemiology and drug safety (2020)

Rapid monitoring results will inform ongoing policy decisions related to the Biosimilars Initiative, in terms of impacts on both patient health and health services utilization.

Keyphrases

rheumatoid arthritis
public health
healthcare
mental health
loop mediated isothermal amplification
case report
quality improvement
health information
disease activity
drug induced
ankylosing spondylitis
interstitial lung disease
social media
systemic sclerosis
quantum dots